Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104728 · ClinicalTrials.gov registry record · NA
Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Terminated
- Registry status
- NA
- Development phase
- 42
- Enrollment target
NCT00104728 is a NA study that was terminated before completion, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 42 participants.
The verdict
NCT00104728, a NA study, was terminated before completion, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- TERMINATED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who are undergoing surgery for stage I, stage II, or stage III non-small cell lung cancer.
Interventions
- DRUG ZD1839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2004-10 |
| Est. Completion | 2009-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104728
The ClinicalTrials.gov registry entry for NCT00104728 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ZD1839 is the first listed.
NCT00104728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00104728 about?
NCT00104728 is a clinical study titled "Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates". RATIONALE: Gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving gefitinib before surgery may shrink the tumor so it can be removed. PURPOSE: This phase II trial is studying how well gefitinib works in treating patients who are undergoing surger...
What is the current status of trial NCT00104728?
This trial is currently terminated. It is a NA study. The enrollment target is 42 participants. The study started on 2004-10. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00104728?
The interventions under investigation include: ZD1839 (DRUG).
Who is sponsoring clinical trial NCT00104728?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.